Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin
Chandrasekaran, B.; Dimling, J.; Capizzi, R.L.
Cancer Treatment Reports 71(2): 195-196
1987
ISSN/ISBN: 0361-5960 PMID: 2948640 Document Number: 304680
Mice bearing the P388/S or P388/ADR (doxorubicin-resistant) leukemia were treated with menogaril or mitoxantrone. Both drugs were highly effective against P388/S but were ineffective against the doxorubicin-resistant subline, indicating cross-resistance. These observations may be of use in the design of clinical trials with these drugs.
Document emailed within 1 workday
Related Documents
Xu, H.-B.; Li, L.; Liu, G.-Q. 2009: Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells Die Pharmazie 64(10): 660-665Carter, G.L.; Cory, J.G. 1988: Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells Cancer Research 48(20): 5796-5799
Mansouri, A.; Henle, K.J.; Benson, A.M.; Moss, A.J.; Nagle, W.A. 1989: Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia Cancer Research 49(10): 2674-2678
Eng, W.K.; McCabe, F.L.; Tan, K.B.; Mattern, M.R.; Hofmann, G.A.; Woessner, R.D.; Hertzberg, R.P.; Johnson, R.K. 1990: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase i content Molecular Pharmacology 38(4): 471-480
Majlessipour, F.; Kwock, R.; Martin-Aragon, S.; Weinberg, K.I.; Avramis, V.I. 2001: Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities Anticancer Research 21(1a): 11-22
Fichtner, I.; Reipert, B.; Becker, M.; Lemm, M. 1993: In vivo characterization of immunogenicity of a mitoxantrone-resistant murine P388 leukemia In Vivo 7(1): 73-79
Yoshida, T.; Shimizu, K.; Hayakawa, T.; Mogami, H.; Sakamoto, Y.; Egawa, T. 1987: Overcoming of ACNU resistance in an ACNU-resistant subline of rat C6 glioma in vivo through enhanced effect of ACNU by calmodulin inhibitor No Shinkei Geka. Neurological Surgery 15(3): 261-267
Kiss, Z.; Deli, E.; Shoji, M.; Koeffler, H.P.; Pettit, G.R.; Vogler, W.R.; Kuo, J.F. 1987: Differential effects of various protein kinase C activators on protein phosphorylation in human acute myeloblastic leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a Cancer Research 47(5): 1302-1307
Bassan, R.; Lerede, T.; Buelli, M.; Borleri, G.; Bellavita, P.; Rambaldi, A.; Barbui, T. 1998: A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia Haematologica 83(5): 422-427
Ramu, A.; Cohen, L.; Glaubiger, D. 1984: Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells Cancer Research 44(5): 1976-1980
Baran, Y.; Gunduz, U.; Ural, A.U. 2006: Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine Experimental Oncology 28(2): 163-165
Ferreira, M-José.U.; Duarte, Nélia.; Gyémánt, N.; Radics, R.; Cherepnev, G.; Varga, A.; Molnár, J. 2006: Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells Anticancer Research 26(5a): 3541-3546
Bellamy, W.T.; Dalton, W.S.; Kailey, J.M.; Gleason, M.C.; McCloskey, T.M.; Dorr, R.T.; Alberts, D.S. 1988: Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage Cancer Research 48(22): 6365-6370
Volm, M.; Mattern, J.; Pommerenke, E.W. 1991: Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210 Anticancer Research 11(2): 579-585
Giuliani, F.C.; Kaplan, N.O. 1980: New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse Cancer Research 40(12): 4682-4687
Harker, W.G.; Slade, D.L.; Parr, R.L.; Feldhoff, P.W.; Sullivan, D.M.; Holguin, M.H. 1995: Alterations in the topoisomerase Ii alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase Ii beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line Cancer Research 55(8): 1707-1716
Prokhorova, E.V. 1972: Formation of staphylococcal strains resistant to antitumor antibiotics and their cross resistance Antibiotiki 17(6): 546-551
Kyo, T.; Dohy, H. 1988: Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 51(8): 1641-1652
Mankhetkorn, S.; Dubru, F.; Hesschenbrouck, J.; Fiallo, M.; Garnier-Suillerot, A. 1996: Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells Molecular Pharmacology 49(3): 532-539
Cheung, W.K.; Aiache, M.; Yacobi, A.; Silber, B.M. 1988: Changes in tissue concentrations of 14C-doxorubicin caused by mitoxantrone, mithramycin A and vinblastine in the rat Research Communications in Chemical Pathology and Pharmacology 59(1): 61-68